HUTCHMED (China) Limited (HK:0013) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HUTCHMED (China) Limited has announced the launch of its novel cancer therapy, FRUZAQLA® (fruquintinib), in Japan, in partnership with Takeda. This milestone follows the approval by Japan’s Ministry of Health, Labour and Welfare, marking FRUZAQLA® as the first oral targeted treatment for metastatic colorectal cancer in Japan in over a decade. The drug, already available in the US, Europe, and China, highlights the strategic global expansion of HUTCHMED’s cancer treatment portfolio.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Nvidia Stock Could Take a Beating from Supply Snags on Blackwell Chips
- ‘This Is Just Pure Hype,’ Says Top Investor About Tesla Stock
- Will Palantir Stock Crash to $28? Jefferies Sounds the Alarm
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
